Segovia Pérez C, Maín Pérez A, Corral Cuevas L, González María E, Raquejo Grado M A, Martín Tomero E, de Pablos Heredero A, López Rodríguez A, Hidalgo Santos J C
Centros de Salud de Rioza, Nava de la Asunción, Villacastín y Sepúlveda, Segovia.
Aten Primaria. 2000 Dec;26(10):670-6. doi: 10.1016/s0212-6567(00)78749-x.
To investigate whether there is a relationship between the quality of the clinical history (CH) in primary care and metabolic control of patients with diabetes (DM).
Retrospective and observational.
15 health centres in the Segovia Area.
315 diabetic patients, selected at random from among those with a record of the type of DM, date and outcome of at least one HbA1c and treatment at the time of the most recent HbA1c.
The quality of the clinical histories was measured through the mean of recording of the following items in the 13 months previous to the most recent HbA1c: weight and height, peripheral pulses, sensitivity, foot examination, creatinine, proteinuria, microalbuminuria, glucaemia levels, back of eye, ECG, and diet, tobacco and alcohol counselling. Other variables that could condition the HbA1c, chronic pathologies and those related to DM, were gathered too. Of patients treated with diet or oral diabetic drugs, patients with a clinical history of < or = 49% quality had a mean HbA1c of 7.40%, whereas those with CH of > or = 50% quality had an average of 6.94% (0.46 difference; 95% CI, 0.03-0.90; p = 0.038). This drop was not attributable to age, gender, years of evolution or BMI differences. The risk of having an HbA1c > or = 7.5% is double in patients with a CH of < or = 49% quality than in those with CH of > or = 50% quality (OR = 2.06; 95% CI, 1.14-3.72). In insulin-treated patients, no association between CH quality and HbA1c was found.
Follow-up of the recommendations for clinical action is associated with better metabolic control in diabetics treated with diet--oral diabetic drugs. This association was not found in insulin-treated patients.
调查初级保健中临床病史(CH)的质量与糖尿病(DM)患者代谢控制之间是否存在关联。
回顾性观察研究。
塞哥维亚地区的15个健康中心。
315例糖尿病患者,从有DM类型记录、至少一次糖化血红蛋白(HbA1c)日期及结果以及最近一次HbA1c时治疗情况的患者中随机选取。
通过在最近一次HbA1c之前13个月记录以下项目的平均值来衡量临床病史质量:体重和身高、外周脉搏、感觉、足部检查、肌酐、蛋白尿、微量白蛋白尿、血糖水平、眼底、心电图以及饮食、烟草和酒精咨询。还收集了其他可能影响HbA1c的变量、慢性疾病以及与DM相关的变量。在接受饮食或口服降糖药治疗的患者中,临床病史质量≤49%的患者平均HbA1c为7.40%,而临床病史质量≥50%的患者平均为6.94%(差异为0.46;95%可信区间,0.03 - 0.90;p = 0.038)。这种下降并非归因于年龄、性别、病程或体重指数差异。临床病史质量≤49%的患者HbA1c≥7.5%的风险是临床病史质量≥50%患者的两倍(比值比 = 2.06;95%可信区间,1.14 - 3.72)。在接受胰岛素治疗的患者中,未发现临床病史质量与HbA1c之间存在关联。
遵循临床行动建议与接受饮食 - 口服降糖药治疗的糖尿病患者更好的代谢控制相关。在接受胰岛素治疗的患者中未发现这种关联。